Volume : 10, Issue : 12, December – 2023
Title:
NEW MODALITIES OF DIABETES MANAGEMENT
Authors :
Sharifa Salem Alshehri, Khalid Majdua Alshehri, AFRAH KHALID ALQABLI, Elham Hassan Nami4, Amal J Alfaifi, zainab ahmed almobarak, Feher Mohammed Alturkistani, Salma Mansour Ali Al Turayf, Mohammed Abdullah Almutairi, NEDAA MOHAMMED A ALROMAILI, Mohammed Abdulmajeed M Alabbad, Sohaib Adel Bahamdeen, Reem Abdullah Al-Thibani, NOUF MOHAMMED A ABOISHAH, AMANY MOHAMMAD MOHAMMAD SAHLI
Abstract :
Introduction: Diabetes mellitus (DM) is becoming more common at an alarming rate around the world. Diabetes’s standing has shifted over the last three generations; previously considered a minor disease of the elderly, it is now one of the main causes of morbidity and mortality among middle-aged and young individuals. Chronic diseases such as Type 1 and Type 2 diabetes are caused by high blood glucose levels, insulin sensitivity, and insulin shortage. Traditional diabetes treatments, such as insulin sensitization and insulin secretion, have unfavorable side effects, resulting in patient noncompliance and medication discontinuation. Nanotechnology in diabetes research has stimulated the development of innovative methods for monitoring glucose and delivering insulin, which have the potential to improve the quality of life for diabetic patients. In addition to insulin and oral hypoglycemic medications, other therapies such as -cell regeneration and gene therapy are presently used to control diabetes.
Aim of the Study: The current review focuses on nanocarrier-based medication delivery technologies and new diabetes treatment options.
Methodology: The review is comprehensive research of PUBMED since the year 2002 to 2022
Conclusion: Diabetes care is in serious need of improvement. Diabetes is becoming more common at an unprecedented rate, putting enormous economic strain on healthcare spending and the cost of treating diabetic complications. While there are numerous relevant new treatment medications, none (save insulin or insulin analogs) are successful alone in achieving appropriate glycemic control. As a result, combinations of complimentary medications are becoming increasingly significant in illness therapy. Furthermore, the development of novel medications that target other targets will improve our ability to successfully treat this crucial disease.
Keywords: diabetes mellitus, insulin, blood glucose level, nanocarrier, treatment strategies.
Cite This Article:
Please cite this article in press Sharifa Salem Alshehri et al., New Modalities Of Diabetes Management, Indo Am. J. P. Sci, 2023; 10 (12).
Number of Downloads : 10
References:
1. Karamanou M, Protogerou A, Tsoucalas G, Androutsos G, & Poulakou-Rebelakou E (2016). Milestones in the history of diabetes mellitus: The main contributors. World journal of diabetes, 7(1), 1.
2. Harding J L, Wander P L, Zhang X, Li X, Karuranga S, Chen H, & Ma R C (2022). The incidence of adult-onset type 1 diabetes: a systematic review from 32 countries and regions. Diabetes Care, 45(4), 994-1006.
3. Mishra V, Nayak P, Sharma M, Albutti A, Alwashmi A S, Aljasir M A, & Tambuwala M M (2021). Emerging treatment strategies for diabetes mellitus and associated complications: An update. Pharmaceutics, 13(10), 1568.
4. He L, Sabet A, Djedjos S, Miller R, Sun X, Hussain M A, & Wondisford F E (2009). Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell, 137(4), 635-646.
5. Rena G, Hardie D G, & Pearson E R (2017). The mechanisms of action of metformin. Diabetologia, 60(9), 1577-1585.
6. Proks P, Reimann F, Green N, Gribble F, & Ashcroft F (2002). Sulfonylurea stimulation of insulin secretion. Diabetes, 51(suppl_3), S368-S376.
7. Stonehouse A H, Darsow T, & Maggs D G (2012). Incretin‐based therapies. Journal of diabetes, 4(1), 55-67.
8. Weisman A, Bai J W, Cardinez M, Kramer C K, & Perkins B A (2017). Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. The lancet Diabetes & endocrinology, 5(7), 501-512.
9. Rai V K, Mishra N, Agrawal A K, Jain S, & Yadav N P (2016). Novel drug delivery system: an immense hope for diabetics. Drug delivery, 23(7), 2371-2390.
10. Wang M, Wang C, Ren S, Pan J, Wang Y, Shen Y, & Zhao X (2022). Versatile oral insulin delivery nanosystems: from materials to nanostructures. International Journal of Molecular Sciences, 23(6), 3362.
11. Sercombe L, Veerati T, Moheimani F, Wu S Y, Sood A K, & Hua S (2015). Advances and challenges of liposome assisted drug delivery. Frontiers in pharmacology, 6, 286.
12. Plaza-Oliver M, Santander-Ortega M J, & Lozano M V (2021). Current approaches in lipid-based nanocarriers for oral drug delivery. Drug Delivery and Translational Research, 11, 471-497.
13. Hasan A A, Madkor H, & Wageh S (2013). Formulation and evaluation of metformin hydrochloride-loaded niosomes as controlled release drug delivery system. Drug delivery, 20(3-4), 120-126.
14. Liu X, Li C, Lv J, Huang F, An Y, Shi L, & Ma R (2020). Glucose and H2O2 dual-responsive polymeric micelles for the self-regulated release of insulin. ACS Applied Bio Materials, 3(3), 1598-1606.
15. Ndisang J F, Rastogi S, & Vannacci A (2015). Insulin resistance, type 1 and type 2 diabetes, and related complications 2015. Journal of diabetes research, 2015.
16. Calne R Y, Gan S U, & Lee K O (2010). Stem cell and gene therapies for diabetes mellitus. Nature Reviews Endocrinology, 6(3), 173-177.
17. Sadrzadeh N, Glembourtt M J, & Stevenson C L (2007). Peptide drug delivery strategies for the treatment of diabetes. Journal of pharmaceutical sciences, 96(8), 1925-1954.